A new Hungarian patent can successfully cure COVID-19 complications
Clinical trials investigating the effectiveness of fluvoxamine therapy in the treatment of pulmonary scarring (pulmonary fibrosis) will begin in early November, according to a publication on the Semmelweis University’s website. The research program is implemented in cooperation with Semmelweis University, the Hungarian Academy of Sciences, and the university spin-off company SigmaDrugs.
Quibit writes that, according to a report published on the university’s website, COVID-19 can damage the body in two ways: one is when it exacerbates pre-existing conditions, such as cardiovascular problems, kidney disease, or oncological symptoms, and the other case is when it triggers an overly strong immune response. The latter is caused by a so-called cytokine storm, which can result in severe pneumonia and multiorgan damage, and fluvoxamine therapy can help doctors treat lung scarring.
Andrea Fekete, an associate professor at Semmelweis University and co-founder of SigmaDrugs biotech, says that the basic idea is simple: previous neurobiological research has shown that activating the Sigma-1 receptor reduces inflammatory processes in the brain. The Sigma-1 receptor in the central nervous system was first described in the 1970s. Basically, its role was linked to brain functions, for exampe, it was assigned a regulatory function connected to memory and behaviour. Research over the past decade and a half has shown that this receptor can be present in other areas of the body, and one of its many functions is to reduce inflammation, says the program manager.
- U.S. hits over 100,000 single-day COVID-19 cases after Election day
- All about the Hungarian curfew: what can we do and what is forbbiden?
A research team led by Andrea Fekete at the Pediatric Clinic No. I confirmed that a protective mechanism similar to the central nervous system works in the lungs, kidneys, or eyes. Their discovery that Sigma-1 plays a role in renal oxygen deprivation and may be a good target for medicine development in this regard was first published in 2016 and has since been patented in the US, Japan, China, and Israel, published by several well-known journals.
If clinical trials have not even begun, how can you claim in your headline that this ‘can successfully cure complications’? I thought that this sort of misinformation was illegal in Hungary. Neither Facebook nor Twitter would publish this nonsense without a warning banner. It’s not just bad journalism is it also potentially dangerous. This article should be amended or withdrawn.